Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in Hospitalized COVID-19 Patients with Severely Reduced Kidney Function
2020-005416-22Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir with Placebo (2 arms). Primary endpoint: Composite risk of death or invasive mechanical ventilation through Day 29. Started Feb 2021; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005416-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005416-22.